Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

By: www.fool.com|

Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?

J&J is a healthcare giant performing very well right now, but it won't be a great fit for every investor.

By Reuben Gregg Brewer -- Nov 22, 2026 at 8:38AM EST

Key Points

  • Johnson & Johnson is a leader in the pharmaceutical and medical device sectors.
  • JNJ is a Dividend King with an above-market yield.
  • The healthcare giant's valuation could turn some investors away from the stock.

Johnson & Johnson (JNJ +1.25%) is the kind of investment that you buy and hold for the long term. However, that doesn't mean it will be a great option for every investor. While it could be a buy for a conservative dividend investor today, many others will likely be better off putting the stock on their wish list. Here's why.

Johnson & Johnson runs a great business

It is important to understand that Johnson & Johnson has an incredible business history. Founded more than 100 years ago, the business has proven resilient, changing over time to serve its customers and reward its shareholders. Today, the company is an industry leader in both the pharmaceutical and medical devices segments of the broader healthcare sector.

Image source: Getty Images.

There are many ways that J&J's success could be highlighted, but one of the best is probably its dividend track record. The healthcare giant has increased its dividend for 64 consecutive years. That not only makes J&J a Dividend King but also gives it the longest streak of any healthcare company. A company can't build a dividend track record like that by accident; it requires a strong business model that gets executed well in good times and bad.

During the third quarter, J&J again showed how well it is run, increasing its full-year guidance for revenues and earnings. On the top line, the healthcare behemoth now projects $101.2 billion in revenue, with the bottom line at $11.10 per share. Those are both modest improvements over the previous guidance, but the direction is what's important. If you own this stock, you should be pleased with the third-quarter 2026 update.

Who should own Johnson & Johnson?

The problem is that Wall Street knows that J&J is a well-run company. That's why the yield is 1.9%, above the market's tiny 1% and the average healthcare stock's 1.3%, but still unlikely to be enticing to investors looking to maximize the income their portfolios generate. The yield is also near its lowest levels in the past decade. That speaks to another problem: valuation.

Johnson & Johnson's price-to-sales ratio is 6.8x compared to a five-year average of 4.8x. Its price-to-earnings ratio is 42x, compared with a long-term average of 24x. And its price-to-book ratio is 8.2x versus a five-year average of 5.8x. While the P/E ratio has been biased higher by one-time charges, the overall statement here is that J&J is expensive. So value investors will probably want to stay on the sidelines.

There is, however, a place for Johnson & Johnson if you are a conservative, income-oriented investor who places a high value on dividend consistency. This is, basically, a situation where investors are paying up for quality. That said, if you are patient, you could probably buy the stock with a more attractive yield and valuation during a broad market downturn. So even here, it could be a wish-list stock. But if you are looking to buy a diversified healthcare stock that you can count on for the long term, it deserves strong consideration despite the premium price tag.

No investment is perfect, not even J&J

It would be wonderful if great companies were also cheap and had above-average dividend yields. That's just not how Wall Street works most of the time. If you have a value focus or favor high-yield stocks, J&J probably won't fit your portfolio right now. Keep it on your wish list, just in case a market downdraft opens up a buying opportunity. However, if what you are looking for is a reliable dividend stock with an above-market yield, paying a premium for J&J could still be worth it if you have a long enough time horizon.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

You may also like

iconiconiconiconiconiconiconiconicon
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:bd@weex.com
VIP Program:support@weex.com